P38α/JNK signaling restrains erythropoiesis by suppressing Ezh2-mediated epigenetic silencing of Bim

被引:0
|
作者
Ping Hu
Angel R. Nebreda
Helmut Hanenberg
Garrett H. Kinnebrew
Mircea Ivan
Mervin C. Yoder
Marie-Dominique Filippi
Hal E. Broxmeyer
Reuben Kapur
机构
[1] Herman B Wells Center for Pediatric Research,Department of Pediatrics
[2] Indiana University School of Medicine,Department of Pediatrics III
[3] Indianapolis,Division of Hematology/Oncology, Department of Medicine
[4] Institute for Research in Biomedicine (IRB Barcelona). Barcelona Institute of Science and Technology,Division of Experimental Hematology and Cancer Biology
[5] University Children’s Hospital Essen,Department of Microbiology/Immunology
[6] University of Duisburg-Essen,undefined
[7] Indiana University School of Medicine,undefined
[8] Indianapolis,undefined
[9] Cincinnati Children’s Research Foundation,undefined
[10] University of Cincinnati College of Medicine,undefined
[11] Indiana University School of Medicine,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
While erythropoietin (EPO) constitutes the major treatment for anemia, a range of anemic disorders remain resistant to EPO treatment. The need for alternative therapeutic strategies requires the identification of mechanisms that physiologically restrain erythropoiesis. Here we show that P38α restrains erythropoiesis in mouse and human erythroblasts independently of EPO by integrating apoptotic signals during recovery from anemia. P38α deficiency promotes JNK activation through increased expression of Map3k4 via a negative feedback mechanism. JNK prevents Cdk1-mediated phosphorylation and subsequent degradation by Smurf2 of the epigenetic silencer Ezh2. Stabilized Ezh2 silences Bim expression and protects erythroblasts from apoptosis. Thus, we identify P38α/JNK signaling as a molecular brake modulating erythropoiesis through epigenetic silencing of Bim. We propose that inhibition of P38α, by enhancing erythropoiesis in an EPO-independent fashion, may provide an alternative strategy for the treatment of anemia.
引用
收藏
相关论文
共 50 条
  • [21] EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis
    Heather M. Moore
    Maria E. Gonzalez
    Kathy A. Toy
    Ashley Cimino-Mathews
    Pedram Argani
    Celina G. Kleer
    Breast Cancer Research and Treatment, 2013, 138 : 741 - 752
  • [22] Regulator of G protein signaling 16 restrains apoptosis in colorectal cancer through disrupting TRAF6-TAB2-TAK1-JNK/p38 MAPK signaling
    Shen, Hao
    Yuan, Jie
    Tong, Dafeng
    Chen, Bingchen
    Yu, Enda
    Chen, Guanglei
    Peng, Cheng
    Chang, Wenjun
    Jifu, E.
    Cao, Fuao
    CELL DEATH & DISEASE, 2024, 15 (06):
  • [23] Securinine inhibits the tumor growth of human bladder cancer cells by suppressing Wnt/β-catenin signaling pathway and activating p38 and JNK signaling pathways
    Xie, Liping
    Liang, Shiqiong
    Jiwa, Habu
    Zhang, Lulu
    Lu, Qiuping
    Wang, Xiaoxuan
    Luo, Lijuan
    Xia, Haichao
    Li, Ziyun
    Wang, Jiayu
    Luo, Xiaoji
    Luo, Jinyong
    BIOCHEMICAL PHARMACOLOGY, 2024, 223
  • [24] A new synthetic antitumor naphthoquinone induces ROS-mediated apoptosis with activation of the JNK and p38 signaling pathways
    de Almeida, Patricia D. O.
    Barbosa Jobim, Gleyce dos Santos
    dos Santos Ferreira, Caio Cesar
    Bernardes, Lucas Rocha
    Dias, Rosane B.
    Schlaepfer Sales, Caroline B.
    Valverde, Ludmila de F.
    Rocha, Clarissa A. G.
    Soares, Milena B. P.
    Bezerra, Daniel P.
    de Carvalho da Silva, Fernando
    do Carmo Cardoso, Mariana Filomena
    Ferreira, Vitor Francisco
    Brito, Larissa F.
    de Sousa, Lirlandia Pires
    de Vasconcellos, Marne C.
    Lima, Emerson S.
    CHEMICO-BIOLOGICAL INTERACTIONS, 2021, 343
  • [25] EGCG blocks TGFβ1-induced CCN2 by suppressing JNK and p38 in buccal fibroblasts
    Chang, Jenny Zwei-Chieng
    Yang, Wan-Hsien
    Deng, Yi-Ting
    Chen, Hsin-Ming
    Kuo, Mark Yen-Ping
    CLINICAL ORAL INVESTIGATIONS, 2013, 17 (02) : 455 - 461
  • [26] EGCG blocks TGFβ1-induced CCN2 by suppressing JNK and p38 in buccal fibroblasts
    Jenny Zwei-Chieng Chang
    Wan-Hsien Yang
    Yi-Ting Deng
    Hsin-Ming Chen
    Mark Yen-Ping Kuo
    Clinical Oral Investigations, 2013, 17 : 455 - 461
  • [27] Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling
    Gruenbaum, Lore M.
    Schwartz, Racheline
    Woska, Joseph R., Jr.
    DeLeon, Rodney P.
    Peet, Gregory W.
    Warren, Thomas C.
    Capolino, Alison
    Mara, Lisa
    Morelock, Maurice M.
    Shrutkowski, Anthony
    Jones, Jessi Wildeson
    Pargellis, Christopher A.
    BIOCHEMICAL PHARMACOLOGY, 2009, 77 (03) : 422 - 432
  • [28] Xiaoyao powder improves endometrial receptivity via VEGFR-2-mediated angiogenesis through the activation of the JNK and P38 signaling pathways
    He, Ming
    Li, Li
    Wei, Xuecong
    Geng, Dandan
    Jiang, Huabo
    Xiangxiang, Gu
    Zhang, Yu
    Du, Huilan
    JOURNAL OF ETHNOPHARMACOLOGY, 2022, 282
  • [29] Rutaecarpine alleviates renal ischemia reperfusion injury in rats by suppressing the JNK/p38 MAPK signaling pathway and interfering with the oxidative stress response
    Wang, Chunhua
    Hao, Zongyao
    Zhou, Jun
    Zhang, Li
    Sun, Yexiang
    Liang, Chaozhao
    MOLECULAR MEDICINE REPORTS, 2017, 16 (01) : 922 - 928
  • [30] EZH2 enhances proliferation and migration of trophoblast cell lines by blocking GADD45A-mediated p38/MAPK signaling pathway
    Qian, Xuefang
    Zhang, Yuying
    BIOENGINEERED, 2022, 13 (05) : 12583 - 12597